Table 5.
Prognostic value of stratification scores dichotomized at an intermediate–high-risk level.
| Score | Sensitivity | Specificity | PLR | PPV | Outcome |
|---|---|---|---|---|---|
| Scores including Plasma Lactate | |||||
| ESC 2019 + lactate [60] | 0.33 (0.16 to 0.55) |
0.95 (0.92 to 0.97) |
6.27 (3.11 to 12.66) |
0.27 | In-hospital adverse outcome |
| Bova + lactate [64] | 0.46 (0.34 to 0.58) |
0.91 (0.90 to 0.92) |
5.16 (3.55 to 7.13) |
0.26 | Adverse 7-day outcome |
| TELOS [64] | 0.19 (0.11 to 0.30) |
0.95 (0.95 to 0.96) |
3.94 (2.04 to 7.15) |
0.21 | Adverse 7-day outcome |
| Scores without plasma lactate | |||||
| Bova [66] | 0.48 (0.30 to 0.67) |
0.86 (0.82 to 0.90) |
3.41 (2.11 to 5.52) |
0.19 | Adverse 30-day outcome |
| ESC 2014 [66] | 0.80 (0.61 to 0.91) |
0.69 (0.64 to 0.73) |
2.60 (2.00 to 3.30) |
0.15 | Adverse 30-day outcome |
| ESC 2019 [67] | 0.52 (0.34 to 0.70) |
0.79 (0.77 to 0.82) |
2.5 (1.7 to 3.7) |
0.07 | In-hospital adverse outcome |
ESC: European Society of Cardiology; PLR: positive likelihood ratio; PPV: positive predictive value.